MARKET

ABT

ABT

Abbott Labs
NYSE

Real-time Quotes | Nasdaq Last Sale

113.19
-0.58
-0.51%
After Hours: 112.84 -0.35 -0.31% 19:48 05/25 EDT
OPEN
113.20
PREV CLOSE
113.77
HIGH
114.94
LOW
112.35
VOLUME
3.92M
TURNOVER
0
52 WEEK HIGH
142.60
52 WEEK LOW
104.63
MARKET CAP
198.19B
P/E (TTM)
26.13
1D
5D
1M
3M
1Y
5Y
First lady welcomes second big shipment of baby formula from Europe
Jill Biden and Surgeon General Vivek Murthy welcomed the delivery Wednesday of a second shipment of tens of thousands of pounds of baby formula that the Biden administration is importing from Europe to ease critical supply shortages in the U.S.
marketwatch.com · 2h ago
U.S. will cover baby formula cost for low-income families -agriculture agency
reuters.com · 7h ago
Despite 'lost confidence' in Abbott, FDA OKd baby formula plant reopening
The FDA entered into a consent decree with Abbott (NYSE:ABT) to reopen its troubled Sturgis, Mich., baby formula plant even though the agency "lost confidence" in the company's safety and
Seekingalpha · 7h ago
U.S. FDA defends baby formula shortage response in Congress
reuters.com · 9h ago
House lawmakers take on baby-formula shortage: ‘We expect answers from the FDA, Abbott’
emocratic and Republican lawmakers on Wednesday are putting a spotlight on makers of baby formula, the Biden administration and industry experts due to an ongoing formula shortage, with two House hearings taking place on Capitol Hill.
marketwatch.com · 10h ago
Report on Abbott baby formula plant took months to reach top FDA official - WaPo
A whistleblower report sent to the U.S. FDA in October 2021 alleging unclean conditions at an Abbott (NYSE:ABT) baby formula plant didn't reach the agency's top food safety official until
Seekingalpha · 11h ago
FDA Allows Import Of 2M Baby Formula Cans Amid Supply Shortage: Reuters
Benzinga · 11h ago
Abbott to restart production of EleCare formula on June 4
Abbott Laboratories said Tuesday it plans to restart manufacturing formula at its plant in Sturgis, Mich., on June 4, and it will prioritize production of EleCare, a hypoallergenic, amino acid-based formula. The company said that batch of Elecare formula i...
marketwatch.com · 13h ago
More
No Data
Learn about the latest financial forecast of ABT. Analyze the recent business situations of Abbott Labs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

30.43%Strong Buy
56.52%Buy
8.70%Hold
4.35%Under-perform
0.00%Sell
Analyst Price Target
The average ABT stock price target is 140.17 with a high estimate of 158.50 and a low estimate of 111.00.
High158.50
Average140.17
Low111.00
Current 113.19
EPS
Actual
Estimate
0.430.871.301.73
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 3.33K
Institutional Holdings: 1.40B
% Owned: 79.69%
Shares Outstanding: 1.75B
TypeInstitutionsShares
Increased
1.05K
43.97M
New
133
4.91M
Decreased
1.03K
54.09M
Sold Out
163
7.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.19%
Healthcare Equipment & Supplies
-0.39%
Key Executives
Chairman/Chief Executive Officer/Director
Robert Ford
Chief Financial Officer/Executive Vice President - Finance
Robert Funck
Executive Vice President/General Counsel/Secretary
Hubert Allen
Executive Vice President/Director of Human Resources
Mary Moreland
Executive Vice President
John Capek
Executive Vice President
Lisa Earnhardt
Executive Vice President
John Ginascol
Executive Vice President
Daniel Salvadori
Executive Vice President
Andrea Wainer
Senior Vice President
Gregory Ahlberg
Senior Vice President
Christopher Calamari
Senior Vice President
Michael Dale
Senior Vice President
Sammy Karam
Senior Vice President
Joseph Manning
Senior Vice President
Louis Morrone
Senior Vice President
Michael Pederson
Senior Vice President
Jared Watkin
Senior Vice President
Alejandro Wellisch
Senior Vice President
Randel Woodgrift
Vice President - Finance/Controller
Philip Boudreau
Lead Director/Independent Director
William Osborn
Independent Director
Robert Alpern
Independent Director
Sally Blount
Independent Director
Patricia Gonzalez
Independent Director
Michelle Kumbier
Independent Director
Darren McDew
Independent Director
Nancy Mckinstry
Independent Director
Michael Roman
Independent Director
Daniel Starks
Independent Director
John Stratton
Independent Director
Glenn Tilton
No Data
No Data
About ABT
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its products include a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. It offers cardiovascular and metabolic products, including Lipanthyl, TriCor, Teveten, Teveten Plus, Physiotens, and Synthroid.

Webull offers kinds of Abbott Laboratories stock information, including NYSE:ABT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABT stock methods without spending real money on the virtual paper trading platform.